BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 990 filers reported holding BAXTER INTL INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,473,950 | +248.1% | 542,500 | +274.1% | 0.03% | +222.2% |
| Q1 2023 | $5,881,200 | +57592.8% | 145,000 | +72400.0% | 0.01% | – |
| Q4 2022 | $10,194 | -100.0% | 200 | -100.0% | 0.00% | -100.0% |
| Q3 2022 | $30,759,000 | -19.0% | 571,097 | -3.4% | 0.06% | -14.9% |
| Q2 2022 | $37,959,000 | -17.2% | 590,993 | -1.5% | 0.07% | +3.1% |
| Q1 2022 | $45,869,000 | -7.6% | 599,802 | +5.5% | 0.06% | -26.1% |
| Q4 2021 | $49,652,000 | +17.2% | 568,423 | +10.5% | 0.09% | +11.4% |
| Q3 2021 | $42,375,000 | -7.6% | 514,603 | -8.4% | 0.08% | -11.2% |
| Q2 2021 | $45,843,000 | -5.2% | 561,588 | -0.4% | 0.09% | -15.2% |
| Q1 2021 | $48,374,000 | +7.8% | 563,632 | -0.1% | 0.10% | 0.0% |
| Q4 2020 | $44,894,000 | -2.3% | 564,436 | -2.5% | 0.10% | -12.5% |
| Q3 2020 | $45,937,000 | -3.3% | 578,641 | +3.5% | 0.12% | -16.1% |
| Q2 2020 | $47,496,000 | +2.8% | 558,820 | +0.0% | 0.14% | -14.4% |
| Q1 2020 | $46,191,000 | +3.5% | 558,681 | +5.0% | 0.17% | +22.8% |
| Q4 2019 | $44,611,000 | -4.7% | 531,932 | -2.2% | 0.14% | -8.7% |
| Q3 2019 | $46,826,000 | +4.1% | 543,995 | -1.3% | 0.15% | +2.8% |
| Q2 2019 | $44,981,000 | +3.3% | 551,109 | +1.3% | 0.14% | -2.0% |
| Q1 2019 | $43,524,000 | +21.5% | 544,258 | +0.0% | 0.15% | +4.2% |
| Q4 2018 | $35,814,000 | -22.6% | 544,047 | -9.4% | 0.14% | -6.0% |
| Q3 2018 | $46,290,000 | +7.0% | 600,446 | +2.5% | 0.15% | +3.4% |
| Q2 2018 | $43,250,000 | +21.6% | 585,525 | +7.5% | 0.15% | +11.5% |
| Q1 2018 | $35,572,000 | +4.1% | 544,568 | +2.8% | 0.13% | +18.0% |
| Q4 2017 | $34,160,000 | +76.9% | 529,521 | +66.9% | 0.11% | +63.2% |
| Q3 2017 | $19,305,000 | +479.0% | 317,305 | +476.9% | 0.07% | +353.3% |
| Q2 2017 | $3,334,000 | +79.0% | 55,000 | +53.3% | 0.02% | +114.3% |
| Q1 2017 | $1,863,000 | +392.9% | 35,869 | +320.0% | 0.01% | +600.0% |
| Q4 2016 | $378,000 | +7460.0% | 8,540 | +8440.0% | 0.00% | – |
| Q3 2016 | $5,000 | -97.9% | 100 | -98.0% | 0.00% | -100.0% |
| Q2 2016 | $233,000 | -98.2% | 5,115 | -97.3% | 0.00% | -96.9% |
| Q1 2016 | $13,267,000 | -52.6% | 191,059 | -73.9% | 0.03% | -73.6% |
| Q4 2015 | $27,966,000 | -51.0% | 732,629 | -10.5% | 0.12% | -44.7% |
| Q4 2013 | $57,038,000 | -43.0% | 819,028 | -46.3% | 0.22% | -50.7% |
| Q3 2013 | $100,103,000 | -28.6% | 1,526,329 | -24.5% | 0.44% | -27.7% |
| Q2 2013 | $140,127,000 | – | 2,022,768 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |